HOME > LATEST

LATEST

BUSINESS Izervay, Vorzzz, Dormicum Syrup Now Available in Japan

November 28, 2025
ORGANIZATION Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture

November 28, 2025
ORGANIZATION Labor Federation Files Request for 5% Drug Price Hike with Health Minister

November 28, 2025
REGULATORY Japan Doles Out Orphan Tags to IgAN Drugs and Lots More

November 28, 2025
BUSINESS Meiji Seeks Label Expansion for Laserphyrin in Cervical Intraepithelial Neoplasia

November 28, 2025
BUSINESS Jardiance Tops 7 Categories in October Promotion Rankings: Intage

November 28, 2025
COLUMN AI in HR: Navigating the Ethical Minefield

November 28, 2025
REGULATORY New Govt Casts Pharma as Core Industry, Minister Says at Public-Private Confab

November 27, 2025
REGULATORY MHLW Floats Prefectural Bodies for Regional Formularies, LLP Copay Hike Gains Traction: LDP-Ishin Talks

November 27, 2025
BUSINESS Otsuka’s Sibeprenlimab Earns FDA’s Accelerated Nod for IgAN

November 27, 2025
REGULATORY MHLW Orders Label Revisions for Anticoagulants, Ondexxya, Tracleer, and More

November 27, 2025
BUSINESS Japan PIII Trial Begins for Kagoshima University Spinout’s Oncolytic Virus

November 27, 2025
REGULATORY Lawmakers Hold Cross-Party Study Session on Social Security

November 27, 2025
BUSINESS Mochida, Ayumi Curb Shipments of Humira Biosimilar 40 mg amid Surging Orders

November 27, 2025
BUSINESS Toray Out-Licenses Peripheral Neuropathy Drug to Sanodyne

November 27, 2025
REGULATORY US Unveils Up to 85% Price Cuts for IRA Round-2; Astellas’ Xtandi on the List

November 27, 2025
BUSINESS Renalys’ IgAN Drug Nets Positive PIII Data, 2026 Japan Filing on Track

November 27, 2025
BUSINESS Rolling Submission for Leqembi SC Starting Dose Completed in US

November 27, 2025
ORGANIZATION Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks

November 26, 2025
BUSINESS Taisho Touts Low Next-Day Carryover for New Insomnia Drug Vorzzz

November 26, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…

COMMENTARY

Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?

By Hayate Horiguchi

Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…